PMID- 31135445
OWN - NLM
STAT- MEDLINE
DCOM- 20210719
LR  - 20210719
IS  - 1533-4058 (Electronic)
IS  - 1533-4058 (Linking)
VI  - 28
IP  - 6
DP  - 2020 Jul
TI  - Chromogenic and Silver in Situ Hybridization for Identification of HER 2 
      Overexpression in Breast Cancer Patients: A Systematic Review and Meta-Analysis.
PG  - 411-421
LID - 10.1097/PAI.0000000000000773 [doi]
AB  - INTRODUCTION: This systematic review has the purpose to characterize the accuracy 
      of chromogenic in situ hybridization (CISH) and silver in situ hybridization 
      (SISH), in comparison to fluorescence in situ hybridization (FISH) in the 
      identification of human epidermal growth factor receptor-2 (HER2) overexpression 
      and to inform decisions about test selection. MATERIALS AND METHODS: We searched 
      MEDLINE and EMBASE databases using these eligibility criteria: studies evaluating 
      invasive breast cancer samples which examined agreement between CISH or SISH, and 
      FISH, and reported sensitivity, specificity, or concordance. We performed a 
      bivariate meta-analysis of sensitivity and specificity using a generalized linear 
      mixed model. We used likelihood ratio tests from meta-regression to compare 
      accuracy between HER2 tests. RESULTS: The search identified 4475 articles, of 
      which 32 were included. The summary estimates for sensitivity and specificity 
      were 0.91 [95% confidence interval (CI), 0.85-0.95], and 0.97 (95% CI, 0.93-0.99) 
      for SISH; 0.97 (95% CI, 0.83-1.00) and 0.99 (95% CI, 0.96-1.00) for single-probe 
      CISH; and, 0.98 (95% CI, 0.92-0.99) and 0.98 (95% CI, 0.91-0.99) for dual-probe 
      CISH. Significantly higher sensitivity was reported for dual-CISH than SISH (chi: 
      5.36; P=0.02) when compared with the reference test FISH. CONCLUSIONS: The 
      agreement between new bright field tests (SISH and CISH) and FISH is high (>/=92%). 
      Indirect comparison of HER2 tests indicated that overall CISH performance exceeds 
      that of SISH. The pooled estimates from this meta-analysis summarize the current 
      published literature and, in addition to other factors such as costs 
      differentials, can help inform future HER2 test selection decisions.
FAU - Grazziotin, Luiza R
AU  - Grazziotin LR
AD  - Departments of Community Health Sciences.
FAU - Dada, Bukky R
AU  - Dada BR
AD  - Departments of Community Health Sciences.
FAU - de la Rosa Jaimes, Carolina
AU  - de la Rosa Jaimes C
AD  - Departments of Community Health Sciences.
FAU - Cheung, Winson Y
AU  - Cheung WY
AD  - Oncology, University of Calgary, Calgary, AB, Canada.
FAU - Marshall, Deborah A
AU  - Marshall DA
AD  - Departments of Community Health Sciences.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Appl Immunohistochem Mol Morphol
JT  - Applied immunohistochemistry & molecular morphology : AIMM
JID - 100888796
RN  - 0 (Arabidopsis Proteins)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (OCP3 protein, Arabidopsis)
RN  - 0 (Transcription Factors)
RN  - 3M4G523W1G (Silver)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Arabidopsis Proteins
MH  - Breast Neoplasms/*diagnosis/*metabolism
MH  - Female
MH  - Homeodomain Proteins
MH  - Humans
MH  - In Situ Hybridization/methods
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Receptor, ErbB-2/genetics/*metabolism
MH  - Sensitivity and Specificity
MH  - Silver/metabolism
MH  - Transcription Factors
EDAT- 2019/05/29 06:00
MHDA- 2021/07/20 06:00
CRDT- 2019/05/29 06:00
PHST- 2019/05/29 06:00 [pubmed]
PHST- 2021/07/20 06:00 [medline]
PHST- 2019/05/29 06:00 [entrez]
AID - 00129039-202007000-00001 [pii]
AID - 10.1097/PAI.0000000000000773 [doi]
PST - ppublish
SO  - Appl Immunohistochem Mol Morphol. 2020 Jul;28(6):411-421. doi: 
      10.1097/PAI.0000000000000773.